Ukusetyenziswa kweziyobisi ezinokuzikhusela kunokunika uncedo olubalulekileyo ngaphezu kweComomid
I-Femara (letrozole) yonyango lomlomo elisetyenziselwa ukuvuselela i-ovulation kubasetyhini abane- polycystic ovary syndrome (i-PCOS) kunye nokungabonakali kwemvelo. Ngoxa i-Femara ivunywe yi-US Food and Drug Administration ukuba isetyenziswe njengesilonda somhlaza webele, isetyenzisiwe ngaphandle kwileyibhile ngoogqirha be-fertility ukususela ngo-2001 kuba kunemiphumo emibini yeComidid (clomiphene) kunye nomngcipheko ophantsi we-multiple ukukhulelwa.
I-Clomid iyona ndlela yokuqala yokukhetha ukwelashwa kwabantwana besifazane abane-PCOS. Uphando olutshanje, nangona kunjalo, lucebise ukuba i-Femara inokunikela ngezinga eliphezulu kakhulu lokukhulelwa ngaphakathi kweli nani labasetyhini
I-Femara iphinda isetyenziswe kwiziganeko zokuxhathisa kwe-Clomid xa iComid iyakwazi ukuvuselela i-ovulation okungenani imijikelezo emithathu yonyango kunye naphezu kokunyuka kwamayeza.
Indlela yokusebenzisa i-Femara
U-Femara unikezwa nge-2.5-milligram ephuzi, ipilisi ephetshwe ngefilimu. Ngokusekelwe xa ixesha lakho liqala, ugqirha uya kukucebisa xa uqala unyango. Unyango luya kuthathwa kwiintsuku ezintlanu ezilandelelanayo.
Ezinye iingcali zokuzala zicebisa ukuthatha iipilisi kwiintsuku ezi-3, 4, 5, 6 no-7 zomjikelezo wakho. Abanye bavumela iintsuku ezingama-5, 6, 7, 8 kunye no-9. Nangona kukho i-ingxoxo ngokuphi na okukhethekileyo, uphando lwangoku lubonakala lubonisa ukuba amazinga okuphumelela aphezulu-okanye angaphantsi.
Ngokusekelwe xa unyango luqala, unokulindela xa kufuneka uqale ukulala ngesondo:
- Ukuba uqale unyango ngomhla we-3 , mhlawumbi uhamba ngexesha elithile phakathi komhla wesi-14 kunye nomhla we-17 womjikelezo wakho. Ukukhulelwa, ufuna ukuqala ukulala ngesondo ngaphambi kokuba ugule. Kule meko, uza kuqala ukulala ngesondo yonke imihla (okanye yonke imihla) ukusuka ngomhla we-11 kunye nokuphela ngomhla we-18.
- Ukuba uqalise unyango ngomhla we-5, uya kukhwela phakathi kweentsuku ezili-16 no-19. Kule meko, uza kuqala ukulala ngesini phakathi kweentsuku 13 no-21.
Ukubhekisa bhetele ixesha lokuvuthwa, ungasebenzisa i- kitty predictor kit . Uya kuqalisa ukuvavanya xa usugqibile unyango kunye nokuvavanywa kwimihla ngemihla de ufumana umphumo omuhle (obonisa ukuba usondele kwi-ovulation). Lo ngumqondiso wokuqala ukulala ngesondo.
I-Femara ingasetyenziselwa ukwelashwa kwe- intrauterine insemination (IUI) . I-Clomid ngamanye amaxesha ibhalwe phantsi kunye ne-Femara kwaye ithathwa ndawonye ngeentsuku ezifanayo.
Imiphumela
I-Letrozole isebenza ngokunciphisa amanqanaba e-estrogen ukwenzela ukuba kukhuthazwe i-ovulation. Amanqanaba e-estrojeni aphantsi kwanaluphi na uhlobo angenza ibhinqa libe neempawu. Ezi ziqhelekileyo zibonwa ngokusetyenziswa kwe-Femara ziquka:
- Ukukhathala
- Utywala
- Intloko
- Ukuqhawula
- Ukutshisa okushisayo
- I sweats
- Umbono ongezantsi
- Isisu esimoshakele
- Iintlungu zesisu
- Unzima ukulala
- Ukutshatyalaliswa okanye ukuphuma kwelanga ngokungavamile
Ukuba ufumana umbono ophazamisayo okanye naziphi na iimpawu ezibonakala zibi kakhulu, qha ga mshelana nodokotela wakho.
Ngelixa lingaqabile, abafazi abathatha u-Femara bangahlakulela imeko eyaziwa ngokuba yi- ovarian hyperstimulation syndrome (OHSS) engabonakaliswa ngeempawu ezivela ekunqandeni kunye nehudo ukuya ekuphefumuleni okufutshane kunye nentlungu yesifuba.
Impumelelo ye-Femara
Kukho ubungqina obandayo bokuthi i-Femara inokuba yinto efanelekileyo ngakumbi kubasetyhini abane-PCOS abajongene neengxaki ze-ovulation.
Ngokomxholo we-2014 opapashwe kwi- New England Journal of Medicine , ama-27.5 ekhulwini abafazi nabakwa-PCOS abathatha u-Femara bazalwa ngokuphumelelayo ngokumalunga nama-19.5 ekhulwini abathatha uComomid. Uphando olufanayo lubonise inzuzo kwezinye iindawo:
- Izinga lokunyuka kwe-ovulation laliphezulu kunye ne-Femara (iipesenti ezingama-61.7) xa kuthelekiswa neComomid (iipesenti ezingama-48.3).
- Kwakukho izinga eliphezulu lokuzalwa phakathi kwabasetyhini abagqithiseleyo abane-PCOS abasebenzisa i-Femara.
- Kwakukho ukukhulelwa okumbalwa kwabasetyhini abasebenzisa i-Femara (iipesenti ezi-3.2) xa kuthelekiswa nalabo basebenzisa iComomid (iipesenti ezingama-7.4).
Umngcipheko wokulahlekelwa kokukhulelwa, okwangoku, wawuninzi-okanye-ngaphantsi kokufanayo kunye nezidakamizwa (i-Femara 31.8 yeepesenti ngokumelene namaComid 28.2%).
Ngokufanayo, uphando olwenziwe ngo-2015 olupapashwe kwi- PLoS One lugqiba ukuba akukho mvelaphi ephawulekayo kwinqanaba elipheleleyo lesiphene sokuzalwa phakathi kwabantwana abazalelwa koomama ababelethwe ngokwemvelo okanye abo basebenzisa i-Femara okanye i-Clomid.
> Imithombo:
> Franik, S .; Kremer, J ;, Nelen, W; kunye ne-Farquhar, C. "I-Aromatase inhibitors yabasetyhini abasetyhini kunye ne-polycystic ovary syndrome." I- Cochrane Database Syst Rev. 2014; 2: I-DOI 10.1002 / 14651858.CD010287.
> Kar S. "Ubungqina obukhoyo obuxhasa i-letrozole yokukhutshwa kwe-ovulation." J Hum Reprod Sci. 2013; 6 (2): 93-8.
> Legro, R .; Brzyski, R .; Diamond, M. et al. "I-Letrozole ngokumelene ne-clomiphene yokungabikho kwintsholongwane kwi-polycystic ovary syndrome." N Engl J Med. 2014; 371 (2): 119-29.
> Sharma, S; Ghosh, S; Singh, S. et al. Ukungqinelani kobungqingili phakathi kweentsana ezizalwe ngokulandela i-Letrozole okanye i-Clomiphene ye-Unfertility Treatment. PLoS ONE. 2015; 9 (10): e108219.